That’s why you need a jab and I don’t.
-
As of today ICMag has his own Discord server. In this Discord server you can chat, talk with eachother, listen to music, share stories and pictures...and much more. Join now and let's grow together! Join ICMag Discord here! More details in this thread here: here.
Covid 19 mrna Vaccines...Yes/No?
- Thread starter gaiusmarius
- Start date
That’s why you need a jab and I don’t.
Sorry not familiar with the jingle. 1000 pardons. Carry on.
I'm pro all those things and take good care of myself. Some very fit and healthy people have died of this virus. I am very comfortable with my decision to vaccinate and will get a booster if recommended.'
Fitness enthusiast, 42, who rejected vaccine, dies of Covid
John Eyers had been climbing mountains four weeks before his death in intensive care
A “fit and healthy” 42-year-old who loved climbing mountains and lifting weights has died of Covid-19 after refusing to get vaccinated, leaving his twin sister and mother heartbroken.
The two women warned others not to think they are invulnerable to the dangers of the virus.
The father of one, John Eyers, a construction expert from Southport in Merseyside, was described by his sister Jenny McCann as “the fittest, healthiest person I know”.
She added that her brother had been climbing Welsh mountains and camping in the wild four weeks before his death.
https://www.theguardian.com/world/20...-dies-of-covid
yeah lame ass paywall. apparently it's a WSJ exclusive for a few days/weeks and then it'll be available elsewhere
That looks legit. What a bunch of crap. Somebody drew a picture and you eat it up.
sad anecdote, for sure, but i will gladly take those odd: one "fit and healthy" death out of the 1,000,000 deaths to covid (?) in usa.
but was this dude really "fit and healthy" - reading his bio brings up questions. where are the demographic studies and blood work? - to be really sure this is not just misinformation and scare propaganda.
congress has dropped funding for more vaccines----
https://www.nbc29.com/2022/03/17/federal-funding-covid-19-tests-treatment-vaccines-drying-up/
CDC has admitted the PCR tests are worthless and suggest using alternate tests----
https://www.cdc.gov/csels/dls/locs/...-Changes_CDC_RT-PCR_SARS-CoV-2_Testing_1.html
CDC eliminates 25% of Pediatric COVID Deaths Overnight, Blames It on a Coding Error----
https://www.thegatewaypundit.com/20...c-covid-deaths-overnight-blames-coding-error/
CONFIRMED: Additional Data Corroborates Excess Deaths Among Millennials Since the Experimental Vaccines Were Mandated – Confirms Covid is Not the Cause----
https://www.thegatewaypundit.com/20...l-vaccines-mandated-confirms-covid-not-cause/
almost 50K cov2 tests recalled due to high number off false positives----
https://www.thegatewaypundit.com/20...-recalled-high-number-false-positive-reports/
9 of 10 covid deaths in canada were fully vaccinated-----
https://dailyexpose.uk/2022/03/19/d...irmed-9-in-10-covid-deaths-triple-vaccinated/
https://www.nbc29.com/2022/03/17/federal-funding-covid-19-tests-treatment-vaccines-drying-up/
CDC has admitted the PCR tests are worthless and suggest using alternate tests----
https://www.cdc.gov/csels/dls/locs/...-Changes_CDC_RT-PCR_SARS-CoV-2_Testing_1.html
CDC eliminates 25% of Pediatric COVID Deaths Overnight, Blames It on a Coding Error----
https://www.thegatewaypundit.com/20...c-covid-deaths-overnight-blames-coding-error/
CONFIRMED: Additional Data Corroborates Excess Deaths Among Millennials Since the Experimental Vaccines Were Mandated – Confirms Covid is Not the Cause----
https://www.thegatewaypundit.com/20...l-vaccines-mandated-confirms-covid-not-cause/
almost 50K cov2 tests recalled due to high number off false positives----
https://www.thegatewaypundit.com/20...-recalled-high-number-false-positive-reports/
9 of 10 covid deaths in canada were fully vaccinated-----
https://dailyexpose.uk/2022/03/19/d...irmed-9-in-10-covid-deaths-triple-vaccinated/
Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching
Lucy Kerr, Flavio A. Cadegiani, Fernando Baldi, Raysildo B. Lobo, Washington Luiz O. Assagra, Fernando Carlos Proença, Pierre Kory, Jennifer A. Hibberd, Juan J. Chamie-Quintero
Published: January 15, 2022 (see history)
DOI: 10.7759/cureus.21272
Cite this article as: Kerr L, Cadegiani F A, Baldi F, et al. (January 15, 2022)
Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching. Cureus 14(1): e21272. doi:10.7759/cureus.21272
Abstract
Background: Ivermectin has demonstrated different mechanisms of action that potentially protect from both coronavirus disease 2019 (COVID-19) infection and COVID-19-related comorbidities. Based on the studies suggesting efficacy in prophylaxis combined with the known safety profile of ivermectin, a citywide prevention program using ivermectin for COVID-19 was implemented in Itajaí, a southern city in Brazil in the state of Santa Catarina. The objective of this study was to evaluate the impact of regular ivermectin use on subsequent COVID-19 infection and mortality rates.
Materials and methods: We analyzed data from a prospective, observational study of the citywide COVID-19 prevention with ivermectin program, which was conducted between July 2020 and December 2020 in Itajaí, Brazil. Study design, institutional review board approval, and analysis of registry data occurred after completion of the program. The program consisted of inviting the entire population of Itajaí to a medical visit to enroll in the program and to compile baseline, personal, demographic, and medical information. In the absence of contraindications, ivermectin was offered as an optional treatment to be taken for two consecutive days every 15 days at a dose of 0.2 mg/kg/day. In cases where a participating citizen of Itajaí became ill with COVID-19, they were recommended not to use ivermectin or any other medication in early outpatient treatment. Clinical outcomes of infection, hospitalization, and death were automatically reported and entered into the registry in real time. Study analysis consisted of comparing ivermectin users with non-users using cohorts of infected patients propensity score-matched by age, sex, and comorbidities. COVID-19 infection and mortality rates were analyzed with and without the use of propensity score matching (PSM).
Results: Of the 223,128 citizens of Itajaí considered for the study, a total of 159,561 subjects were included in the analysis: 113,845 (71.3%) regular ivermectin users and 45,716 (23.3%) non-users. Of these, 4,311 ivermectin users were infected, among which 4,197 were from the city of Itajaí (3.7% infection rate), and 3,034 non-users (from Itajaí) were infected (6.6% infection rate), with a 44% reduction in COVID-19 infection rate (risk ratio [RR], 0.56; 95% confidence interval (95% CI), 0.53-0.58; p < 0.0001). Using PSM, two cohorts of 3,034 subjects suffering from COVID-19 infection were compared. The regular use of ivermectin led to a 68% reduction in COVID-19 mortality (25 [0.8%] versus 79 [2.6%] among ivermectin non-users; RR, 0.32; 95% CI, 0.20-0.49; p < 0.0001). When adjusted for residual variables, reduction in mortality rate was 70% (RR, 0.30; 95% CI, 0.19-0.46; p < 0.0001). There was a 56% reduction in hospitalization rate (44 versus 99 hospitalizations among ivermectin users and non-users, respectively; RR, 0.44; 95% CI, 0.31-0.63; p < 0.0001). After adjustment for residual variables, reduction in hospitalization rate was 67% (RR, 0.33; 95% CI, 023-0.66; p < 0.0001).
Conclusion: In this large PSM study, regular use of ivermectin as a prophylactic agent was associated with significantly reduced COVID-19 infection, hospitalization, and mortality rates.
https://www.cureus.com/articles/8216...score-matching
Lucy Kerr, Flavio A. Cadegiani, Fernando Baldi, Raysildo B. Lobo, Washington Luiz O. Assagra, Fernando Carlos Proença, Pierre Kory, Jennifer A. Hibberd, Juan J. Chamie-Quintero
Published: January 15, 2022 (see history)
DOI: 10.7759/cureus.21272
Cite this article as: Kerr L, Cadegiani F A, Baldi F, et al. (January 15, 2022)
Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching. Cureus 14(1): e21272. doi:10.7759/cureus.21272
Abstract
Background: Ivermectin has demonstrated different mechanisms of action that potentially protect from both coronavirus disease 2019 (COVID-19) infection and COVID-19-related comorbidities. Based on the studies suggesting efficacy in prophylaxis combined with the known safety profile of ivermectin, a citywide prevention program using ivermectin for COVID-19 was implemented in Itajaí, a southern city in Brazil in the state of Santa Catarina. The objective of this study was to evaluate the impact of regular ivermectin use on subsequent COVID-19 infection and mortality rates.
Materials and methods: We analyzed data from a prospective, observational study of the citywide COVID-19 prevention with ivermectin program, which was conducted between July 2020 and December 2020 in Itajaí, Brazil. Study design, institutional review board approval, and analysis of registry data occurred after completion of the program. The program consisted of inviting the entire population of Itajaí to a medical visit to enroll in the program and to compile baseline, personal, demographic, and medical information. In the absence of contraindications, ivermectin was offered as an optional treatment to be taken for two consecutive days every 15 days at a dose of 0.2 mg/kg/day. In cases where a participating citizen of Itajaí became ill with COVID-19, they were recommended not to use ivermectin or any other medication in early outpatient treatment. Clinical outcomes of infection, hospitalization, and death were automatically reported and entered into the registry in real time. Study analysis consisted of comparing ivermectin users with non-users using cohorts of infected patients propensity score-matched by age, sex, and comorbidities. COVID-19 infection and mortality rates were analyzed with and without the use of propensity score matching (PSM).
Results: Of the 223,128 citizens of Itajaí considered for the study, a total of 159,561 subjects were included in the analysis: 113,845 (71.3%) regular ivermectin users and 45,716 (23.3%) non-users. Of these, 4,311 ivermectin users were infected, among which 4,197 were from the city of Itajaí (3.7% infection rate), and 3,034 non-users (from Itajaí) were infected (6.6% infection rate), with a 44% reduction in COVID-19 infection rate (risk ratio [RR], 0.56; 95% confidence interval (95% CI), 0.53-0.58; p < 0.0001). Using PSM, two cohorts of 3,034 subjects suffering from COVID-19 infection were compared. The regular use of ivermectin led to a 68% reduction in COVID-19 mortality (25 [0.8%] versus 79 [2.6%] among ivermectin non-users; RR, 0.32; 95% CI, 0.20-0.49; p < 0.0001). When adjusted for residual variables, reduction in mortality rate was 70% (RR, 0.30; 95% CI, 0.19-0.46; p < 0.0001). There was a 56% reduction in hospitalization rate (44 versus 99 hospitalizations among ivermectin users and non-users, respectively; RR, 0.44; 95% CI, 0.31-0.63; p < 0.0001). After adjustment for residual variables, reduction in hospitalization rate was 67% (RR, 0.33; 95% CI, 023-0.66; p < 0.0001).
Conclusion: In this large PSM study, regular use of ivermectin as a prophylactic agent was associated with significantly reduced COVID-19 infection, hospitalization, and mortality rates.
https://www.cureus.com/articles/8216...score-matching
Budz Lightyear
Member
Budz Lightyear
Member
[No message]
Budz Lightyear
Member
You should be saying that to Pfizer not me. The only thing you contributed towards was their record profits. Lol.
Whatever. Maybe I can find the video…you know, any fool can produce a YouTube. You seem to find them all.
